INCSHR 1210Alternative Names: HR-301210; INCSHR1210; SHR1210
Latest Information Update: 23 Mar 2017
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Incyte Corporation; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action PDCD 1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatocellular carcinoma
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours
- Phase I Breast cancer; Malignant melanoma
Most Recent Events
- 25 Apr 2017 Jiangsu HengRui Medicine Co. plans a phase I trial for Nasopharyngeal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) (NCT03121716)
- 24 Apr 2017 Jiangsu HengRui Medicine plans a phase II trial for Liver cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) (NCT03092895)
- 10 Apr 2017 Jiangsu HengRui Medicine plans a phase III trial for Oesophageal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/unresectable) in China (NCT03099382)